PuSH - Publication Server of Helmholtz Zentrum München

Eyerich, S. ; Metz, M.* ; Bossios, A.* ; Eyerich, K.*

New biological treatments for asthma and skin allergies.

Allergy 75, 546-560 (2020)
Publ. Version/Full Text Postprint Research data DOI PMC
Open Access Green
Allergies are typically endemic, complex and heterogeneous diseases with a high impact at quality of life. Mechanistically, type 2 immune responses involving eosinophil and basophil granulocytes, mast cells and humoral factors such as IgE are key drivers of allergic diseases. Fighting allergic diseases knows three strategies: prevention, symptomatic and causative therapy. While remarkable progress was made in understanding molecular events in allergies as a prerequisite for effective prevention and desensitization, this review article focuses on the most efficient symptomatic treatments-that is using more and more specific antibodies neutralizing particular immune pathways. We highlight and classify recent and upcoming developments in the three prototype chronic allergic diseases allergic asthma, chronic spontaneous urticaria and atopic eczema. In all three examples, biologics such as dupilumab or omalizumab become reliable and efficient therapeutic options. Finally, we give an outlook how a diagnostic and therapeutic workflow might look like in the near future for these three major burdens of society.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Corresponding Author
Keywords Asthma ; Atopic Dermatitis ; Endotype ; Skin Allergy ; Treatment ; Urticaria; Chronic Spontaneous Urticaria; Humanized Monoclonal-antibody; Anti-cd20 Rituximab Treatment; Eczema Atopic-dermatitis; Eosinophilic Asthma; Double-blind; European Guidelines; Qge031 Ligelizumab; Global Burden; In-vitro
ISSN (print) / ISBN 0105-4538
e-ISSN 1398-9995
Journal Allergy
Quellenangaben Volume: 75, Issue: 3, Pages: 546-560 Article Number: , Supplement: ,
Publisher Wiley
Publishing Place 111 River St, Hoboken 07030-5774, Nj Usa
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute for Allergy Research (IAF)